Table 2.

FPRs ligands developed as therapeutic drugs in cardiovascular diseases (CVDs).

Compound	Interaction	Therapeutic Effects
Cmpd17b	Small biased FPR1/FPR2 agonists	Reduction of necrosis in cardiomyocytes subjected to hypoxia–reoxygenation exerting a cardioprotective effect [69]
		Reduction of inflammatory responses associated with reperfusion after an acute MI [69]
ZK-994 and ZK-142	FPR2	Inhibition of neutrophil accumulation in murine hind-limb IRI-induced second-organ lung injury [132]
ACT-389949	FPR2	Protection against heart failure [143]
CGEN-855A	FPR2	Cardioprotective effects in rat and murine myocardial IRI, similar to those reported for the ANXA1 mimetic peptide Ac2-26 [130]
BMS-986235	FPR2	Protective properties in experimental heart failure [144]
compound 43	Dual FPR1/FPR2 agonist	High degree of protection in a model of heart failure [146]
PLGA microspheres encapsulating WKYMVm	FPR2	Induction of neovascularization in vivo hind limb ischemia model [109]